Nostrum Laboratories voluntarily recalls an additional lot of extended release metformin
FDA is alerting patients and health care professionals to Nostrum Laboratories’ voluntary recall of one additional lot of extended release (ER) metformin. The company is recalling the lot because the metformin may contain N-nitrosodimethylamine (NDMA) above the acceptable intake limit.
FDA publishes a recalled metformin list including details about metformin products that have been recalled. Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate; FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).
|
